Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials by Makani, Harikrishna Jayantilal et al.
Efficacy and safety of dual blockade of the
renin-angiotensin system:meta-analysis of randomised
trials
OPEN ACCESS
Harikrishna Makani fellow in cardiovascular medicine 1, Sripal Bangalore director of cardiovascular
outcomes group, assistant professor of medicine 2, Kavit A Desouza fellow in cardiovascular
medicine1, Arpit Shah resident in internal medicine1, Franz HMesserli professor of clinical medicine1
1Division of Cardiology, St Luke’s Roosevelt Hospital, Columbia University College of Physicians and Surgeons, 1000 10th Avenue, New York, NY
10019, USA; 2The Leon H Charney Division of Cardiology, New York University School of Medicine, New York, NY, USA
Abstract
Objective To compare the long term efficacy and adverse events of
dual blockade of the renin-angiotensin system with monotherapy.
Design Systematic review and meta-analysis.
Data sources PubMed, Embase, and the Cochrane central register of
controlled trials, January 1990 to August 2012.
Study selection Randomised controlled trials comparing dual blockers
of the renin-angiotensin system with monotherapy, reporting data on
either long term efficacy (≥1 year) or safety events (≥4 weeks), and with
a sample size of at least 50. Analysis was stratified by trials with patients
with heart failure versus patients without heart failure.
Results 33 randomised controlled trials with 68 405 patients (mean age
61 years, 71% men) and mean duration of 52 weeks were included.
Dual blockade of the renin-angiotensin system was not associated with
any significant benefit for all cause mortality (relative risk 0.97, 95%
confidence interval 0.89 to 1.06) and cardiovascular mortality (0.96, 0.88
to 1.05) compared with monotherapy. Compared with monotherapy,
dual therapy was associated with an 18% reduction in admissions to
hospital for heart failure (0.82, 0.74 to 0.92). However, compared with
monotherapy, dual therapy was associated with a 55% increase in the
risk of hyperkalaemia (P<0.001), a 66% increase in the risk of
hypotension (P<0.001), a 41% increase in the risk of renal failure
(P=0.01), and a 27% increase in the risk of withdrawal owing to adverse
events (P<0.001). Efficacy and safety results were consistent in cohorts
with and without heart failure when dual therapy was compared with
monotherapy except for all cause mortality, which was higher in the
cohort without heart failure (P=0.04 v P=0.15), and renal failure was
significantly higher in the cohort with heart failure (P<0.001 v P=0.79).
Conclusion Although dual blockade of the renin-angiotensin system
may have seemingly beneficial effects on certain surrogate endpoints,
it failed to reduce mortality and was associated with an excessive risk
of adverse events such as hyperkalaemia, hypotension, and renal failure
compared with monotherapy. The risk to benefit ratio argues against the
use of dual therapy.
Introduction
The concept of dual blockade of the renin-angiotensin system
originated from an experimental model1 purporting to show a
“synergistic” effect between angiotensin converting enzyme
(ACE) inhibitors and angiotensin receptor blockers. The concept
seemed so logical and appealing that seemingly beneficial
changes in surrogate endpoints such as blood pressure,
proteinuria, and endothelial dysfunction became accepted as a
free pass for dual blockade having cardioprotective and
nephroprotective effects. Despite a lack of solid evidence on
the safety and efficacy of dual blockade of the renin-angiotensin
system this type of therapy has been mentioned in several sets
of guidelines.2-4 Thus dual therapy was commonly used in
patients with hypertension and with diabetes or proteinuria, or
both and also to a lesser extent in those with heart failure
resistant to treatment. Even patients with uncomplicated essential
hypertension were not entirely able to escape this fashionable
trend. In the United States more than 200 000 patients are
currently treated with dual blockade of the renin-angiotensin
system, most of them by the combination of an angiotensin
receptor blocker and ACE inhibitor (70%).5 6 Some other
combinations are also used, such as two ACE inhibitors (15%),
two angiotensin receptor blockers (5%), and ACE inhibitors or
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angiotensin receptor blockers in combination with a direct renin
inhibitor (8%).5 The long term efficacy and safety of dual
blockade is not, however, well defined.
We compared the long term efficacy of dual blockade of the
renin-angiotensin system (any two of ACE inhibitors,
angiotensin receptor blockers, or aliskiren) with monotherapy
and evaluated adverse events in patients receiving dual therapy
compared with monotherapy.
Methods
We systematically searched PubMed, Embase, and the Cochrane
central register of controlled trials (Cochrane Library Issue 6,
June 2012) using the key terms “ACE inhibitors”, “angiotensin
receptor blockers”, “direct renin inhibitors” and using the names
of individual drugs (see supplementary table 1). The search was
restricted to randomised controlled trials in humans and in peer
reviewed journals from 1990 to August 2012. No language
restriction was applied. We checked the reference lists of the
reviewed articles and original studies identified by the electronic
search for other potentially eligible articles.
Study selection and data extraction
Two authors (KD and AS) searched the data independently and
in duplicate. Disagreements were resolved by consensus. For
this analysis we extracted the year of publication, baseline
characteristics of the study population, sample size, type of
drug, mean age, study duration, percentage of men, long term
efficacy (all cause mortality, cardiovascular mortality, and
admissions to hospital for heart failure), and safety events
(hyperkalaemia, hypotension, renal failure, and withdrawal
owing to drug related adverse events). Hyperkalaemia was
defined in the included studies as a serum concentration of
potassium greater than 5.5 mmol/L and renal failure as a serum
creatinine concentration greater than 176.8 μmol/L (>2.0mg/dL)
or a doubling of baseline serum creatinine level. The definition
of hypotension in the studies varied from symptomatic
hypotension to evidence of low blood pressure. Withdrawal
owing to drug related adverse events was defined as withdrawal
by a patient as a result of any of the clinical or biochemical
adverse events.
Selection criteria
We screened the trials for eligibility using the following criteria:
randomised clinical trials comparing individual blockers with
a combination of blockers (ACE inhibitor, angiotensin receptor
blocker, or direct renin inhibitor), data on either long term
efficacy (duration ≥1 year) or safety events (duration ≥4weeks),
and a sample size of at least 50. Given the limited number of
trials reporting data on stroke and myocardial infarction, these
outcomes were not evaluated in the study.
Quality assessment
The criteria used for quality assessment were sequence
generation of allocation; allocation concealment; masking of
participants, staff, and outcome assessors; incomplete outcome
data; selective outcome reporting; and other sources of bias, as
recommended by the Cochrane Collaboration.7 We classed
studies with high or unclear risk of bias for any of the first three
components to be of low quality.
Statistical analysis
The statistical analysis was done in line with recommendations
from the Cochrane Collaboration and the preferred reporting
items for systematic reviews and meta-analyses (PRISMA)
guidelines8 using Review Manager (RevMan), version 5.1.7
(Cochrane Collaboration, 2012). Heterogeneity was assessed
using the I2 statistic. I2 is the proportion of total variation
observed between the trials attributable to differences between
trials rather than to sampling error (chance), and we considered
I2 <25% as representing low heterogeneity and I2 >75% as
representing high heterogeneity. We used the random effects
model of DerSimonian and Laird9 to calculate the effect sizes
because of known clinical and methodological heterogeneity of
the studies. All analyses were performed using the intention to
treat principle. Results were calculated by relative risk ratio and
95% confidence intervals using the Mantel-Haenszel method.
We carried out head to head comparisons between individual
blockers and the combination of blockers for both long term
efficacy and safety data. Analysis was stratified by patient
cohorts with and without heart failure. Analysis was also done
to evaluate the safety outcomes between dual blockers (ACE
inhibitors+angiotensin receptor blockers, angiotensin receptor
blockers+aliskiren, ACE inhibitors+aliskiren) and individual
blockers.
Publication bias was estimated visually by funnel plots10 or by
Begg’s test and the weighted regression test of Egger.11 If there
was evidence of publication bias, we applied the trim and fill
method to adjust the results of the meta-analysis.12
Sensitivity analysis
Sensitivity analysis was performed for safety outcomes based
on the cohort of patients with heart failure versus the cohort
without, risk of bias in the trial (low v high), duration of
follow-up (<1 year v ≥1year), and number of patients (<500 v
≥500). We used a test for interaction to estimate differences
between the subgroups.13 Sensitivity analysis was not done for
long term efficacy outcomes because of the limited number of
studies available.
Results
A total of 138 full text articles were assessed for eligibility, of
which 33 met the inclusion criteria (fig 1⇓). The 33 trials14-46
enrolled 68 405 patients with a mean age of 61 (SD 4) years,
71% men, followed-up for a mean duration of 52 weeks (table
1⇓). A combination of anACE inhibitor and angiotensin receptor
blocker was used in 22 trials,14-35 an ACE inhibitor and aliskiren
in three trials,36-38 an angiotensin receptor blocker and aliskiren
in seven trials,39-45 and an ACE inhibitor or angiotensin receptor
blocker with aliskiren in one trial.46
Efficacy data were available from seven trials with a total of 56
824 patients (mean age 65 (SD 2) years, 72% males) and mean
duration of 2.7 years. Safety data were available from all of the
included trials.
Of the 33 trials, 18 reported adequate generation of allocation
sequence and adequate allocation concealment and 24 reported
adequate masking of participants, staff, and outcome assessors.
On the basis of quality assessment, 18 were deemed to be at
low risk of bias and the remainder to be at high risk.
Dual therapy versus monotherapy: efficacy
outcomes
All cause mortality
Data were available from seven trials with a total of 56 824
patients. Overall, 3314 of 21 638 patients (15.3%) died in the
dual therapy group compared with 5286 of 35 186 patients
(15.0%) in the monotherapy group. When compared with
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f360 doi: 10.1136/bmj.f360 (Published 28 January 2013) Page 2 of 15
RESEARCH
monotherapy alone, dual therapy had no benefit on all cause
mortality (relative risk 0.97, 95% confidence interval 0.89 to
1.06, P=0.50, I2=69%, fig 2⇓).
In subgroup analysis, dual therapy showed no benefit for all
cause mortality in the cohort with heart failure (0.92, 0.82 to
1.03, P=0.15), however mortality was increased in the cohort
without heart failure (1.07, 1.00 to 1.14, P=0.04, fig 2). The
difference between these two subgroups was significant
(P=0.02).
Cardiovascular mortality
In six trials 2812 of 19 127 patients (14.7%) died of
cardiovascular causes in the dual therapy group compared with
5128 of 32 687 patients (15.7%) in the monotherapy group.
Dual therapy had no significant benefit on cardiovascular
mortality (0.96, 0.88 to 1.05, P=0.38, I2=59%, fig 3⇓) compared
with monotherapy.
In subgroup analysis, dual therapy had no benefit on
cardiovascular mortality in the cohorts both with heart failure
(P=0.14) and without (P=0.61).
Admissions to hospital for heart failure
In five trials 1825 of 16 728 patients (10.9%0 in the dual therapy
group were admitted to hospital for heart failure compared with
2604 of 25 343 patients (10.3%) in the monotherapy group.
Dual therapy was associated with a 18% reduction in admissions
to hospital for heart failure compared with monotherapy (0.82,
0.74 to 0.92, I2=68%, P=0.0003, fig 4⇓). This was largely driven
by a benefit in the cohort with heart failure (0.77, 0.68 to 0.88,
P=0.0001), although there was a trend towards benefit in the
cohort without heart failure (0.91, 0.82 to 1.01, P=0.07).
Dual therapy versus monotherapy: safety
outcomes
Hyperkalaemia
In 23 trials 2188 of 22 717 patients (9.6%) had hyperkalaemia
in the dual therapy group compared with 1887 of 37 921 patients
(4.9%) in the monotherapy group. Dual therapy was associated
with a 55% increased risk of hyperkalaemia (1.55, 1.32 to 1.82,
I2=50%, P<0.001, fig 5⇓) compared with monotherapy.
In subgroup analysis, the risk of hyperkalaemia increased
significantly in both the cohort with heart failure (P=0.02) and
the cohort without (P<0.001).
Hypotension
In 18 trials 2042 of 23 572 patients (8.7%) had hypotension in
the dual therapy group compared with 2227 of 37 680 patients
(5.9%) in the monotherapy group. Dual therapy was associated
with a 66% increased risk of hypotension (1.66 1.38 to 1.98,
I2=66%, P<0.001, fig 6⇓) compared with monotherapy.
In subgroup analysis, the risk of hypotension increased
significantly in the cohorts both with heart failure (P<0.001)
and without (P=0.002).
Renal failure
In 20 trials 2026 of 24 536 patients (8.3%) had renal failure in
the dual therapy group compared with 2551 of 39 784 patients
(6.4%) in the monotherapy group. Dual therapy was associated
with a 41% increased risk of renal failure (1.41, 1.09 to 1.84,
I2=83%, P=0.01, fig 7⇓) compared with monotherapy.
In subgroup analysis, the risk of renal failure increased
significantly in the cohort with heart failure (2.19, 1.82 to 2.65,
P<0.001) but not in the cohort without (1.04, 0.80 to 1.35,
P=0.76). The difference between these two subgroups was
significant (P<0.001).
Withdrawal owing to drug related adverse events
In 26 trials 4265 of 24 994 patients (17.1%) had withdrawal
owing to drug related adverse events in the dual therapy group
compared with 5825 of 40 247 patients (14.5%) in the
monotherapy group. Dual therapy was associated with a 27%
increase in the risk of withdrawal owing to drug related adverse
events (1.27, 1.21 to 1.32, I2=2%, P<0.001, fig 8⇓) compared
with monotherapy.
In subgroup analysis, the risk of withdrawal owing to drug
related adverse events increased significantly in the cohort both
with heart failure (P<0.001) and without (P=0.0003).
Subgroup analysis of safety outcomes
Comparing the combination of ACE inhibitors and angiotensin
receptor blockers with ACE inhibitors alone, the risk of all
safety outcomes (hyperkalaemia, hypotension, renal failure, and
withdrawal owing to drug related adverse events) increased
significantly with combination treatment: (table 2⇓). Comparing
the combination of ACE inhibitors and angiotensin receptor
blockers with angiotensin receptor blockers alone, the risk of
hypotension and withdrawal owing to drug related adverse
events increased significantly but not the risk of hyperkalaemia
and renal failure with combination treatment (table 2).
Comparing the combination of ACE inhibitors and aliskiren
with ACE inhibitors alone, the risk of hyperkalaemia and
hypotension increased significantly but there was no difference
in the risk of renal failure and withdrawal owing to drug related
adverse events with combination treatment (table 2). Comparing
the combination of ACE inhibitors and aliskiren with aliskiren
alone, the risk of hyperkalaemia, hypotension, renal failure, and
withdrawal owing to drug related adverse effects did not differ
with combination treatment (table 2). Comparing the
combination of angiotensin receptor blockers and aliskiren with
angiotensin receptor blockers alone, the risk of hyperkalaemia
was increased significantly but there was no difference in the
risk of other adverse events (table 2). Comparing the
combination of angiotensin receptor blockers and aliskiren with
aliskiren alone, none of the adverse events differed significantly
between the two groups (table 2). These subgroup analyses are
presented as forest plots in supplementary figures 1-4.
Sensitivity analyses did not show any significant difference in
the groups for hyperkalaemia, hypotension, or withdrawal owing
to drug related adverse effects. The risk of renal failure was
significantly higher in the cohort of patients with heart failure
compared with the cohort without heart failure (P<0.001, see
supplementary table 2).
Significant heterogeneity was present in most of the analyses.
Thus a random variance model was used. No evidence of
publication bias was suggested by visual inspection of funnel
plots or by Egger’s test. The results were not significantly
different after applying the trim and fill method all cause
mortality (relative risk 0.94, 95% confidence interval 0.86 to
1.03), cardiovascular mortality (0.96, 0.86 to 1.04), admissions
to hospital for heart failure (0.82, 0.74 to 0.91), hyperkalaemia
(1.44, 1.22 to 1.70), hypotension (1.59, 1.33 to 1.91), renal
failure (1.47, 1.13 to 1.92), and withdrawal owing to drug related
adverse events (1.27, 1.20 to 1.34) (see supplementary figure
5).
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Discussion
The present analysis evaluating the long term efficacy and safety
of dual blockade of the renin-angiotensin system failed to show
any benefit for all cause mortality and cardiovascular mortality
with dual therapy compared with monotherapy. This is the most
comprehensive review of literature evaluating both the safety
and outcomes of dual therapy. Although compared with
monotherapy dual therapy was associated with a reduction in
admissions to hospital for heart failure mainly in the cohort with
heart failure, the risks of hyperkalaemia, hypotension, renal
failure, and withdrawal owing to drug related adverse events
were significantly increased. Given these facts it may
appropriately be asked why dual therapy was and still is
extensively used to treat many patients with hypertension and
heart failure. With the exception of the CHARM Added trial,18
most if not all data making dual therapy attractive are based on
evidence from surrogate endpoints.
One meta-analysis47 reported “encouraging” evidence that dual
therapy reduced proteinuria by an incremental 20-25% compared
with monotherapy. The COOPERATE study48 even showed that
dual therapy with trandolapril and losartan reduced the risk of
the primary endpoint (time to doubling of serum creatinine level
or end stage renal disease) by 60% better than monotherapy,
thereby becoming one of the most widely quoted studies by the
Lancet.49After such seemingly robust evidencemany physicians
accepted that reduction of albuminuria or proteinuria was
synonymous with nephroprotection. In the CHARM Added
trial,18 in a cohort of 2548 patients with heart failure, dual
blockade of the renin-angiotensin system (candesartan and ACE
inhibitor) significantly reduced the primary outcome of
cardiovascular death or admission to hospital for worsening of
heart failure. As a consequence, dual therapy became more and
more used in patients with hypertension, diabetes, and heart
failure resistant to treatment.
The importance of dual therapy began to changewith publication
of the Ongoing Telmisartan Alone and in Combination with
Ramipril Global Endpoint Trial (ONTARGET).50 Similar to
other studies, in this study the surrogate endpoint albuminuria
was reduced with dual therapy compared with monotherapy.
However, a significant doubling of creatinine level and dialysis
in the combination arm (despite less albuminuria) argued against
a nephroprotection by dual therapy. More recently, authors51
found several inconsistencies in COOPERATE, eventually
leading to retraction of the study by the Lancet.52
In heart failure, the safety issue remained a major concern with
dual therapy. In the CHARM Added trial, hyperkalaemia was
almost five times more common and increased creatinine levels
twice as common with dual therapy than with monotherapy. A
meta-analysis53 in over 18 000 patients with left ventricular
dysfunction showed a significantly increased risk of adverse
events of dual therapy compared with monotherapy, leading to
the discontinuation of dual therapy. Given the adverse effects
and lack of consistent survival benefits, the addition of an
angiotensin receptor blocker to ACE inhibitor therapy in patients
with heart failure should perhaps be reserved only for selected
patients who continue to have symptoms while receiving
monotherapy and cannot tolerate mineralocorticoid antagonists.
Several trials have shown a beneficial effect of aliskiren in
combination with ACE inhibitors or angiotensin receptor
blockers in patients with heart failure or diabetic nephropathy
on surrogate endpoints, such as in proteinuria,41 left ventricular
hypertrophy,39 and neurohormonal changes.36 Our analysis
showed a significantly increased risk of hyperkalaemia with
combination therapywith aliskiren comparedwithmonotherapy.
Similar results were also found in a recent meta-analysis of 10
studies with over 4800 patients.54 The ALTITUDE trial46 was
terminated early because of an increased risk of adverse
outcomes (stroke, hypotension, and hyperkalaemia) when
aliskiren was combined with ACE inhibitors or angiotensin
receptor blockers. As to the mechanism of hypotension, one
author suggested that blockade of the
renin-angiotensin-aldosterone system could trigger the
Bezold-Jarisch reflex sensitised by withdrawal of the effect of
angiotensin II.55 More extensive blockade of the
renin-angiotensin system with two drugs could lead to a
reduction in sympathetic outflow from the brainstem and
excessive vagal tone causing prolonged hypotension and
bradycardia. Conceivably this mechanism might account for
the higher incidence of stroke and hypotension in patients
receiving dual therapy.55 Regulatory agencies such as the Food
and Drug Administration and European Medicines Agency56
recommended avoiding aliskiren in patients with diabetes or
moderate to severe renal dysfunction who are already taking
ACE inhibitors or angiotensin receptor blockers. Of note, the
VA NEPHRON-D multicentre trial57 to assess the effect of
combination of losartan and lisinopril compared with losartan
alone, on the progression of kidney disease in 1850 patients
with diabetes and overt proteinuria was terminated recently for
similar reasons to those of ALTITUDE.
The present data evolving from studies with dual blockade of
the renin-angiotensin system should be a reminder hat many
purported benefits of such therapy was solely based on data
using surrogate endpoints. Surrogate endpoints not uncommonly
fail to emulate hard outcomes endpoints and leapfrogging from
surrogate data cannot substitute for the exposure of patients in
clinical outcome studies.
Strengths and limitations of this
meta-analysis
Our paper had several limitations. As with other meta-analyses,
given the lack of data in each trial, we did not adjust our analysis
for adherence to therapy. Also, the results are subject to
limitations inherent to any meta-analysis based on pooling of
data from different trials with different duration, doses of drugs,
definitions for safety outcomes, and patient groups. Analysis
of safety events is also prone to several biases since the data
vary in each study for quality, incidence, severity, and
adjudication. The reporting may also be influenced by
expectations of the investigators, sponsors, and patients. Despite
all the limitations, this is the most comprehensive analysis
evaluating the safety and efficacy of dual blockade of the
renin-angiotensin system. Despite significant heterogeneity
among the studies, there was no evidence of publication bias
visually and by Egger’s test. The results were fairly consistent
among various subgroups.
Conclusion
Although dual blockade of the renin-angiotensin system may
have seemingly beneficial effects on certain surrogate endpoints,
it failed to reducemortality and was associated with an excessive
risk of adverse events such as hyperkalaemia, hypotension, and
renal failure when compared with monotherapy. The overall
risk to benefit ratio argues against the use of dual therapy.
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What is already known on this topic
Dual blockade of the renin-angiotensin system (RAS) is extensively used for treatment of resistant forms of heart failure, hypertension,
diabetic nephropathy, and proteinuria
The efficacy and safety of dual RAS blockade, however, remains controversial
What this study adds
Although dual RAS blockade reduced admissions to hospital for heart failure (mainly in patients with heart failure), it had no effect on
all cause or cardiovascular mortality
Compared with monotherapy, dual therapy was associated with a significant increase in adverse events such as hyperkalaemia,
hypotension, and renal failure
These considerations of risk-benefit argue against the routine use of dual therapy
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Table 2| Safety outcomes between different drug combinations for dual blockade of the renin-angiotensin system (RAS) compared with
monotherapy
Interaction P valueRelative risk (95% CI), P valueRAS blocker combination v. monotherapy
Angiotensin receptor blockersACE inhibitorsACE inhibitors+angiotensin receptor blockers:
0.261.34 (0.86 to 2.09), 0.191.83 (1.35 to 2.50), 0.0001Hyperkalaemia
0.151.44 (1.04 to 2.01), 0.032.02 (1.46 to 2.80), <0.001Hypotension
0.071.15 (0.92 to 1.43), 0.221.55 (1.23 to 1.96), 0.0002Renal failure
0.181.39 (1.14 to 1.70), 0.0011.21 (1.16 to 1.26), <0.001Withdrawal owing to drug related adverse events
AliskirenACE inhibitorsACE inhibitors+aliskiren:
0.442.55 (1.00 to 6.46), 0.051.70 (1.11 to 2.58), 0.01Hyperkalaemia
NANo studies available1.97 (1.17 to 3.30), 0.02Hypotension
0.160.34 (0.04 to 3.24), 0.351.75 (0.92 to 3.34), 0.09Renal failure
0.450.56 (0.21 to 1.48), 0.240.97 (0.34 to 2.74), 0.95Withdrawal owing to drug related adverse events
AliskirenAngiotensin receptor blockersAngiotensin receptor blockers+aliskiren:
0.861.49 (0.83 to 2.68), 0.181.40 (1.02 to 1.91), 0.04Hyperkalaemia
0.341.02 (0.66 to 1.56), 0.941.62 (0.70 to 3.74), 0.26Hypotension
0.881.02 (0.36 to 2.93), 0.971.13 (0.52 to 2.47), 0.76Renal failure
0.791.19 (0.54 to 2.66), 0.671.06 (0.79 to 1.43), 0.70Withdrawal owing to drug related adverse events
ACE=angiotensin converting enzyme; NA=not applicable.
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Figures
Fig 1 Selection of studies. ACE=angiotensin converting enzyme inhibitor
Fig 2 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for all cause mortality. Error
bars represent 95% confidence intervals and data marker sizes indicate sample sizes of cohorts. ACEi=angiotensin converting
enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor, M-H=Mantel-Haenszel
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Fig 3 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for cardiovascular mortality.
ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor,
M-H=Mantel-Haenszel
Fig 4 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for admissions to hospital for
heart failure. ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor,
M-H=Mantel-Haenszel
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Fig 5 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for hyperkalaemia.
ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; M-H=Mantel-Haenszel
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Fig 6 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for hypotension,
ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor,
M-H=Mantel-Haenszel
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Fig 7 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for renal failure.
ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor,
M-H=Mantel-Haenszel
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Fig 8 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for withdrawal owing to drug
related to adverse events
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